DEBRA Research gGmbH and Dermaliq Therapeutics, Inc. are joining forces to advance cutaneous drug delivery into the skin for Epidermolysis Bullosa (EB).
The strategic, non-exclusive collaboration will initially focus on improving wound-healing and anti-itch therapies, plus developing prophylactic therapies for people with EB. Dermaliq’s proprietary hyliQ technology platform enables touchless delivery of novel drug therapies to fragile, sensitive, or disease-affected skin.
As part of the agreement, DEBRA Research, a non-profit organization dedicated to advancing treatments and cures for EB, has also made a strategic investment in Dermaliq.
“This partnership aligns closely with our mission to accelerate the development of effective, high-impact therapies for people living with EB,” says Dr Christoph Coch MD, Managing Director at DEBRA Research, in a news release. “Dermaliq’s unique technology platform and clinical pipeline offer a promising approach to overcome the limitations of existing topical treatments, particularly for application on the damaged and fragile skin characteristic of EB. We believe this collaboration will play a pivotal role in advancing transformative therapies and improving both medical outcomes and quality of life for those affected by this devastating condition.”
“We are excited to join forces with DEBRA Research to bring our technology to an area of urgent and unmet medical need,” adds Frank Löscher, PhD, CEO of Dermaliq. “This partnership underscores our shared commitment to addressing the urgent needs of people living with this debilitating disorder. With its unique features and exceptional safety profile, hyliQ is ideally suited for the touchless topical treatment of disease-affected and damaged skin. We look forward to the impact this collaboration can bring to the EB community and beyond.”
